Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience-Reference-Cited by-同舟云学术

Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience

Published:2010-04-27 Issue:1 Volume:90 Page:115-116
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Caravita Tommaso,Siniscalchi Agostina,Tendas Andrea,Cupelli Luca,Ales Micaela,Perrotti Alessio,Niscola Pasquale,de Fabritiis Paolo

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-010-0967-4.pdf

Reference8 articles.

1. Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P, Corso A, Di Raimondo F, Falcone A, Ferrara F, Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P, Vacca A, Cavo M, Boccadoro M, Palombo A (2009) Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 82:93–105

2. Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520

3. Harousseau JL (2008) New treatments in multiple myeloma: beyond optimal treatment. Ann Oncol 19(5):68–70

4. Baz R, Walker E, Karam MA et al (2006) Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17:1766–1771

5. Morgan GJ, Schey SA, Wu P et al (2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 137:268–269

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma;International Journal of Cancer;2019-01-22

2. Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma;American Journal of Hematology;2014-02-24

3. Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients;Current Cancer Therapy Reviews;2013-02-01

4. The application and biology of immunomodulatory drugs (IMiDs) in cancer;Pharmacology & Therapeutics;2012-10

5. How to Manage Neutropenia in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2012-02